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Abstract The cblC defect is the most common inborn error of
vitamin B12 metabolism. Despite therapeutic measures, the
long-term outcome is often unsatisfactory. This retrospective
multicentre study evaluates clinical, biochemical and genetic
findings in 88 cblC patients. The questionnaire designed for
the study evaluates clinical and biochemical features at both
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initial presentation and during follow up. Also the develop-
ment of severity scores allows investigation of individual
disease load, statistical evaluation of parameters between the
different age of presentation groups, as well as a search for
correlations between clinical endpoints and potential modify-
ing factors. Results: Nomajor differences were found between
neonatal and early onset patients so that these groups were
combined as an infantile-onset group representing 88 % of all
cases. Hypotonia, lethargy, feeding problems and develop-
mental delay were predominant in this group, while late-
onset patients frequently presented with psychiatric/
behaviour problems and myelopathy. Plasma total homocys-
teine was higher and methionine lower in infantile-onset pa-
tients. Plasma methionine levels correlated with “overall im-
pression” as judged by treating physicians. Physician’s im-
pression of patient’s well-being correlated with assessed
disease load. We confirmed the association between
homozygosity for the c.271dupA mutation and
infantile-onset but not between homozygosity for
c.394C>T and late-onset. Patients were treated with
parenteral hydroxocobalamin, betaine, folate/folinic acid
and carnitine resulting in improvement of biochemical
abnormalities, non-neurological signs and mortality.
However the long-term neurological and ophthalmolog-
ical outcome is not significantly influenced. In summary
the survey points to the need for prospective studies in
a large cohort using agreed treatment modalities and
monitoring criteria.
Introduction
The cblC defect is the most common inborn error of vitamin
B12 (cobalamin, Cbl) metabolism and is caused by mutations
of the MMACHC gene as described in over three hundred
patients (Lerner-Ellis et al 2006; Nogueira et al 2008;
Lerner-Ellis et al 2009).
Cobalamin must be obtained from animal dietary
products such as milk and meat (Fowler 1998). Absorp-
tion of Cbl requires binding to specific proteins in
saliva, proteolytic release and binding to intrinsic factor
in the intestine and uptake into the enterocyte via a
specific receptor. After release from its complex with
intrinsic factor, Cbl enters the circulation bound to
transcobalamin and is taken up into lysosomes through
endocytosis. After release into the cytosol Cbl is con-
verted to its two active co-enzymes, methylcobalamin in
the cytosol and adenosylcobalamin in the mitochondri-
on . Adenosylcoba lamin is the co-enzyme for
methylmalonyl-CoA mutase, deficiency of which results
in methylmalonic aciduria, one of the biomarkers of the
cblC defect. Methylcobalamin is a co-factor for N5-
methyltetrahydrofolate: homocysteine methyltransferase,
deficiency of which results in an increase of homocys-
teine with low levels of methionine, other biochemical
hallmarks of the cblC defect (Fowler 1998).
Clinical presentation and severity of the cblC defect can
vary considerably ranging from severe burden of disease and
even death at an early age to late presenting disabilities
(Bodamer et al 2001). In particular, patients with early onset
of symptoms (<1 year of life) were reported to show an
unfavourable outcome with average survival of less than
10 months and mortality exceeding 25 %, whereas patients
with late onset (defined by the authors as >4 years of life)
survived with a better prognosis following treatment
(Rosenblatt et al 1997).
So far, only one study reports the frequency of symptoms
within a large series of 50 cblC patients (Rosenblatt et al 1997)
and several smaller studies and individual case reports have
focused on particular features (Table 1). In late onset or adult
cases, clinical features include predominantly neurological
disturbances, dementia, myelopathy, and thromboembolic
complications (Shinnar and Singer 1984; Thauvin-Robinet
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et al 2008). A limitation of many of these studies and case
reports is the lack of a clear indication of whether or not
symptoms were initially present at diagnosis or if they devel-
oped during the subsequent course of the disease while pa-
tients were treated.
Treatment with intramuscular hydroxy-Cbl (OH-Cbl), be-
taine and carnitine is reported to improve biochemical abnor-
malities including restoration of plasma methionine values to
normal (Ribes et al 1990; Bellini et al 1992; Bartholomew et al
1998; Andersson et al 1999). Plasma homocyst(e)ine levels or
methionine levels were not improved by the cyano form of
Cbl (Andersson et al 1998) given intramuscularly and/or
folinic acid (Bartholomew et al 1998). The long term outcome
of the cblC defect remains poor in most cases, even when
these therapeutic measures were introduced soon after initial
presentation and in some cases even prenatally (Huemer et al
2005). Further, there is no consensus on the optimal treatment
for this severely debilitating disorder (Martinelli et al 2011b).
This questionnaire based study evaluates clinical find-
ings at initial presentation and during the disease course
whilst treated in 88 cblC deficient patients with the
following aims: i) to evaluate patients according to age
of presentation and to assess possible prognostic indica-
tors; ii) to document the natural history of the cblC
defect over time with particular reference to clinical
signs both at diagnosis and during the course of the
disease; iii) to investigate genotype-phenotype correla-
tions; and iv) to evaluate therapeutic measures.
Table 1 Signs and symptoms in patients with cblC defect as reported in the literature
Frequent signs and symptoms References
• Feeding difficulties
• Haematologic abnormalities
• Hypotonia
• Developmental delay
• Seizures
• Failure to thrive
• Microcephaly
• Pigmentary retinopathy
• Decreased visual acuity
• Nystagmus
Rosenblatt et al 1997; Robb et al 1984; Ricci et al 2005;
Weisfeld-Adams et al 2013
Less frequently reported signs and symptoms
Eye symptoms
• retinal hypopigmentation
• strabismus
• optic atrophy
• maculopathy
Mitchell et al 1986; Tsina et al 2005;
Patton et al 2000; Weisfeld-Adams et al 2013
renal involvement including haemolytic uraemic syndrome Geraghty et al 1992; Sharma et al 2007
Dysmorphic features
• macrocephaly
• facial dysmorphism
• marfanoid features
Cerone et al 1999; Heil et al 2007; Rosenblatt et al 1997
Cardiopulmonary signs
• congenital heart disease
• cardiomyopathy and left ventricular non-compaction
• cor pulmonale
• pulmonary hypertension
Andersson et al 1999; Brandstetter et al 1990; De Bie et al 2009;
Heinemann et al 2001; Iodice et al 2013; Longo et al 2005;
Ogier de Baulny et al 1998; Profitlich et al 2009; Tomaske et al 2001
Neurological signs
• neuropsychiatric disturbances
• abnormal brain stem auditory and visual evoked potentials
• white matter changes/atrophy
• hydrocephalus
• basal ganglia lesions
• sensory peripheral neuropathy
Biancheri et al 2001, 2002; Longo et al 2005; Mamlock et al 1986;
Rosenblatt et al 1997; Roze et al 2003; Smith et al 2006;
Weintraub et al 1991; Weisfeld-Adams et al 2013
Other presentations:
• haemophagocytic lymphohistiocytosis
• protein-losing enteropathy
• neonatal hyperammonemia
• acidosis
• microthrombi
• Thinned corpus callosum
• hyperexia encephalopathy
Ellaway et al 1998; Martinelli et al 2011a; Rosenblatt et al 1997;
Weisfeld-Adams et al 2013; Wu et al 2005; Grünert at al 2011
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Patients and methods
Study population and recruitment of patients
The study was approved by the ethics committee of the Uni-
versity of Basel (Ref.Nr.EK:267/04). A total of 88 patients were
included in the study. Patients were recruited in three ways.
First those from whom cell lines were sent to the University
Children’s Hospital, Basel for confirmation of diagnosis be-
tween January 1987 and May 2005; second, additional patients
reported at a workshop held at the 36th EMG Meeting in
Rimini 2004 (Bodamer and Fowler 2004); third, further con-
firmed cases of the cblC defect known to the contacted physi-
cians. Diagnosis was based on the finding of increased homo-
cysteine, either free or total, and methylmalonic acid in plasma
and/or urine shown not to be due to nutritional vitamin B12
deficiency. In 75 cases the diagnosis was confirmed by studies
of methionine and serine synthesis, propionate incorporation
into cell proteins and Cbl uptake and coenzyme synthesis and
somatic complementation analysis in fibroblasts performed at
the University Children’s Hospital Basel (Fowler and Jakobs
1998). Following discovery of the gene for cblC the molecular
defect was confirmed by mutation analysis.
Questionnaire based survey
A questionnaire was sent to 49 international metabolic centres
with full returns received from 26 centres. The questionnaire
items were developed on the basis of a specialist meeting and
a review of the literature on cblC. Items covering clinical
presentations and features as reported in the literature and
open questions on yet unreported organ involvement at diag-
nosis and during the course were selected. In addition, infor-
mation was requested on personal data, family history, preg-
nancy and birth complications, age at first symptoms and at
diagnosis, biochemical parameters at diagnosis and during the
course, and treatment modalities.
The presence or absence of each specific symptom both at
the time of diagnosis and during the course of the disease was
recorded. Prenatal symptoms were recorded and different
symptoms were grouped according to affected organ systems
(supplementary Table 1)
We developed a severity score in order to estimate the
disease load in the individual both at presentation and during
the course. Thus nutritional symptoms, general development,
neurological symptoms, eye problems, renal, cardiac and hae-
matological involvement as well as abnormalities in brain
MRI scans were numerically assessed and summed to give a
severity score ranging from 0 (no symptoms) to 25 (all symp-
toms present). In addition the physician’s overall impression
on the disease outcome and the present state in each patient
was determined by scoring mental status, visual impairment,
motor development and quality of life. Zero, one and two
points were allocated for normal, moderately impaired and
severely impaired, respectively. Deceased patients were allo-
cated a score of 2 points for each category to give a total
possible score of 8 (see supplementary Table 1). Question-
naires were completed by the physicians caring for the patient
and returned to the University Children’s Hospital Basel.
Following evaluation of initial returns the submitted informa-
tion was incorporated into the database and returned to the
responsible physician for checking and to reply to additional
questions.
In those cases where only free homocysteine disulphide
values were available, an estimate of the total plasma homo-
cysteine was made. This was based on the observation in two
studies (Moat et al 1999; B. Fowler, unpublished data) which
showed that free homocystine is only found in samples in
which total homocysteine exceeds 70 μmol/l. Therefore an
estimate of total homocysteine was calculated by adding 70 to
double the free homocystine concentration. This approach
seems to be justified by the observation that there was no
significant difference of mean values and standard deviation
between the groups of only measured total homocysteine
versus measured plus estimated values (two tailed t-test).
Statistical analysis
Both severity score and physician’s overall impression were
comparedwith various other parameters by statistical analysis.
The various statistical methods used for comparisons of data
are indicated in the results. For all statistical analysis signifi-
cance was assigned to p values below 0.05.
Results
Age distribution and demographic data
The age of presentation in all patients ranged from 0 to
162 months with a median value of 0.91 months. As shown
in Fig. 1, 43 patients presented below 1 month (neonatal
onset), 33 between 1 month and 1 year of age (early onset)
and ten above 1 year of age (late onset). Two patients were
detected by neonatal family screening. There was evidence of
consanguinity in a total of 26 patients.
The ethnic origin was reported as European in 54, unspec-
ified Caucasian in 17, Asian in four with no information in 13.
Among the European patients 27 were from Southern coun-
tries including Italy, Portugal and Spain. The male to female
distribution of 58 to 30 (ratio 1.93) was uneven. A total of ten
subjects had died (supplementary Fig. 1). Seven (sixmale, one
female) patients died before 3 months of age, three female
patients died at 20 months, 4 years and 16 years respectively.
In surviving patients, age at final evaluation ranged from
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9 months to 47 years and 7 months (mean 123.4 months; S.D.
93.5, median 88.5 months).
Clinical symptoms at onset and during disease course
according to subgroups
Figure 2 summarises clinical signs showing the overall fre-
quency of the different findings both at initial clinical presen-
tation and at the last evaluation during the course of the
disease. Symptoms such as personality changes and mental
retardation were only evaluated after the third month of age.
Comparison of the clinical, biochemical and molecular
features between the age groups
Initially all quantitative parameters and individual clinical
severity scores listed in supplementary Table 2 were compared
for patients with neonatal, early and late onset according to the
classification suggested by Rosenblatt et al (1997). Statistical
analysis was performed using the Mann-Whitney U test for
non-parametric variables. Evaluation of data in the neonatal
onset and early onset group revealed few statistically signifi-
cant differences. These were the higher prevalence of micro-
cephaly in the early onset patients both at diagnosis
(p=0.0085) and during the course (p=0.049), and a higher
severity score for general development at diagnosis in early-
onset compared with neonatal-onset patients (p=0.02). Due to
the close clinical similarity and overall lack of statistical
differences between neonatal and early onset patients, these
two groups were combined and termed as “infantile onset” for
further comparisons with late onset patients.
Infantile onset patients showed significantly higher scores
for nutritional signs and microcephaly (all p≤0.015) both at
diagnosis and during the disease course, when compared with
late onset patients. At follow-up alone, significant differences
were found between the two groups for total severity score,
general development, overall impression and eye-related
problems (all p≤0.026). Considering the biochemical param-
eters, the infantile onset group showed lower methionine
levels at diagnosis (median 8.0 vs. 14.0 μmol/l; p=0.017)
and higher homocysteine values at follow-up (55.5 vs.
35.0 μmol/l; p=0.013).
Statistical correlations were analysed using the Spearman
Rank test between various parameters and the severity score at
diagnosis; the severity score during the course and the overall
impression for all patients together and for the different age
groups. This test showed a number of correlations. First, age at
diagnosis and delay in diagnosis correlates with severity score
at diagnosis (p <0.002). Second, total severity score at diag-
nosis correlates with both severity score and overall impres-
sion at follow up (p<0.0001). Third, microcephaly and eye-
related signs at diagnosis and during the course correlate with
severity score at follow-up (p<0.001). In the late onset pa-
tients plasma homocysteine and urine MMA levels correlate
with the severity score and with overall impression (p<0.05),
whereas in infantile onset patients plasma homocysteine alone
at diagnosis correlates with the severity score during the
course. Regardless of the age at presentation, plasma methio-
nine negatively correlates with overall impression at follow-
up (p=0.048). Plasma homocysteine levels during the course
showed a positive correlation with all clinical parameters in
late onset patients.
Brain MRI
Brain MRI findings were available from 64 patients (49
infantile and seven late onset cases). Normal findings were
present in only 19 % of patients. Brain atrophy and white
matter abnormality were seen in both infantile (14/49 and 16/
49 respectively) and late onset (4/7 and 1/7 respectively)
cases. The most striking differences between the age groups
were the finding of hydrocephalus (15/49 patients) and
of basal ganglia lesions (6/49 patients) only in infantile
onset cases.
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Treatment modalities and correlations with clinical outcome
Different treatment modalities were used. Sixty-nine of 76
infantile and nine of 12 late onset patients were treated with
parenteral OH-Cbl. Patients not given OH-Cbl were mainly
ones who died from the disease. Betaine (oral dose ranged
from 100 to 444 mg/kg/day) was used in 67 infantile and six
late onset patients, folate or folinic acid were applied in 57
infantile and four late onset cases (oral dose ranged from 56 to
20,000 μg/kg/day. Carnitine was given to 37 infantile and
two late onset patients. Supplemental methionine was
used only in one patient. No patients were treated with
protein restricted diet.
Contingency tables showed no correlation between the use
of carnitine, betaine or folate and the total severity score
during the course of the disease (two sided Exact Fisher test).
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Furthermore, the Spearman rank test revealed no corre-
lation between the dose of betaine and either median
methionine levels or total homocysteine levels during
the course of the disease.
Genetic analyses
Molecular genetic analysis of MMACHC was performed by
either the group of D.S. Rosenblatt or B. Fowler (personal
communication) in 74 patients (supplementary Table 3). The
most common mutations identified were the c.271dupA and
c.394C>T mutations. Of a total of 148 mutant alleles 73 were
c.271dupA (49 %) and 30 were c.394C>T (20 %). Homozy-
gosity for the c.271dupA mutation was present in 23 patients
(22 with infantile onset) and the c.394C>T mutation in ten
patients (6 with infantile onset). Two infantile onset patients
were homozygous for c.331C>T and a further two were
homozygous for c.217C>T. In addition, 15 private mutations
were identified.
Discussion
This questionnaire based retrospective survey addresses a
comprehensive range of features in the largest number of
patients studied so far with the cblC defect, extending the
report on 50 patients by Rosenblatt et al (1997). We are aware
of a selection bias in the recruitment of either patients from
whom cell lines were sent for confirmation of diagnosis to a
single metabolic laboratory or patients who were known to the
involved metabolic specialists. Nevertheless until now, as in
most inborn errors of metabolism no registry or any other
unbiased patient reporting system has been implemented for
cblC patients. Study patients stemmed mainly from Europe
with only four non-Caucasian and a predominance of cases
from southern Europe reflecting our catchment area rather
than the world-wide ethnicity reported in patients in whom
mutation analysis was undertaken (Lerner-Ellis et al 2009).
The degree of consanguinity was high being reported
in 26 cases.
Regarding gender of the patients there was a clear imbal-
ance towards males, with a male to female ratio close to 2,
which constitutes new information. Whether this is because of
lack of detection or increased intra-uterine mortality for fe-
males can only be speculated on. Ten patients (nine with
infantile onset) died in total, representing 11.4 % of cases
compared with 26 % of patients in the previous cohort
(Rosenblatt et al 1997) possibly reflecting earlier diagnosis
and different or improved treatment modalities.
In contrast to the study by Rosenblatt et al (1997) we
differentiate between clinical and biochemical features present
at diagnosis and those at follow up. This allows a better
understanding of the natural history of the disease and of the
response to treatment. Evaluation of variables in the different
presenting age groups was backed up by statistical analysis
allowing a search for significant correlations between clinical
end points and possible modifying factors.
In addition to assessment of individual features we also
created organ specific and overall severity scores to obtain a
quantitative index for comparison with possible modifying
factors. We are aware of the shortcomings of the approach of
using overall, non standardised scores but it has been shown in
other multi-systemic diseases that severity or disease activity
scores are extremely helpful in clinical practice and evaluation
of treatment and may add to the information deduced from
laboratory parameters. Nevertheless the weighting of symp-
toms and organ damage and the proof of validity and reliabil-
ity of severity scores is a challenging task which may only be
achieved over years and by analysis of larger cohorts
(Gladman et al 2002). Therefore the severity score developed
for our study constitutes a first attempt to establish the general
idea of assessment of patients’ symptoms in a more systematic
manner. Physician’s overall assessment of disease severity is
an established parameter for assessing disease severity in other
multi-systemic diseases (Gutiérrez-Suárez et al 2007; Seid
et al 2013) but has until now only rarely been used in the field
of metabolic diseases.
The previous survey by Rosenblatt et al(1997) reported
patients below 1 year of age as early onset (44 patients) and
above 4 years of age as late onset (six patients). As stated in
the results section we combined the neonatal and early onset
patients as infantile onset. Thus the infantile onset group
contained 88 % of patients, half presenting by 1 month of
age and 38 % between 1 month and 1 year of age. The
remaining 12% of patients presented after the chosen cut off
of 1 year of age and were assigned to the late presentation
group. The overall median age of presentation observed in our
series is close to the 1 month reported in the previous cohort.
The study of the natural course of the cblC defect underlines
that the cblC defect needs to be considered in the differential
diagnosis of a wide range of conditions. At initial presentation
there are several rather non-specific symptoms occurring in
more than half of patients such as hypotonia/weakness, lethar-
gy, feeding difficulties and developmental delay. More specific
signs, related to diffuse microangiopathic damage (Martinelli
et al 2011a, b), include hydrocephalus, detected in about one
third of infantile onset patients, and haemolytic uraemic syn-
drome. Other symptoms were eye-related signs and cardiomy-
opathy, present in less than 10 % of patients, psychiatric disor-
ders, spasticity and myelopathy. Since these complications are
severe and have only been reported anecdotally in this disorder,
our study confirms their importance.
Clinical features were significantly different between the
infantile and late onset patients. Hypotonia/weakness, lethar-
gy, feeding difficulties, failure to thrive, nystagmus, dysmor-
phic features and optic atrophy at diagnosis were all clearly
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more prominent in infantile onset patients. Developmental
delay and seizures were of similar incidence. In late onset
patients, psychiatric changes (personality changes, confusion/
disorientation) and spasticity were fairly common features.
Myelopathy was almost exclusive to the late onset patients.
Apart from the differences in the selection parameters there
was a statistically significant better general condition at pre-
sentation and lack of microcephaly and cardiomyopathy in
late onset patients.
Evaluation of findings during the course of the disease,
following treatment reveals that the non-neurological signs
resolve after treatment. Thus anaemia, acidosis and macrocyto-
sis all disappeared after treatment. Also hypotonia/weakness,
lethargy, feeding difficulties, hydrocephalus, HUS and cardio-
myopathy became less frequent. Since some of these compli-
cations are potentially fatal (e.g. HUS), treatment not only
improves some clinical outcomes but reduces mortality.
In contrast, neurological and ophthalmological problems
such as developmental delay, seizures, failure to thrive, mi-
crocephaly, dysmorphic features, spasticity and optic atrophy
remained at about the same frequency. Also there was an
increase of prevalence of nystagmus, strabismus, pigmentary
retinopathy, visual impairment despite treatment in infantile
onset patients. Therefore the treatment modalities currently
employed here appear not to have completely altered the
disease course, confirming previous assumptions of a poor
long-term neurological prognosis regardless of treatment and
biochemical amelioration (Martinelli et al 2011a, b; Weisfeld-
Adams et al 2013). On-going decline in IQ over time
has been reported by Beauchamp et al (2009) in two
patients despite therapy.
We found no correlation between the dose of either OH-
Cbl or betaine administered and score parameters during the
disease course. A wide variety of treatment modalities have
been applied especially concerning the dose and interval of
medication (e.g. OH-Cbl, betaine), pointing to the need to
understand whether optimisation of known and/or the devel-
opment of new treatment strategies might positively change
the disease course (Dionisi-Vici et al 2013). A recent retro-
spective literature review reporting on both early and late
onset patients suggested that daily treatment with parenteral
OH-Cbl combined with betaine results in a better outcome
(Carrillo-Carrasco and Venditti 2012).
In this regard only one patient in our survey was treated
with supplemental methionine, which has been claimed to be
successful in individual cases of other disorders of defective
remethylation (Kvittingen et al 1997; Abeling et al 1999). The
recent observation both in vitro and in vivo of increased
oxidative stress and of abnormal glutathione status in cblC
defect (Jorge-Finnigan et al 2010; Pastore et al 2013; Richard
et al 2009), may suggest the use of antioxidant therapy to
correct redox state abnormalities and its potentially related
clinical signs.
Of the biochemical features, plasmamethionine was higher
at diagnosis and plasma homocysteine was lower during the
disease course in late onset patients. The finding that only
plasmamethionine levels were correlated with overall impres-
sion is supported by the correlation of methionine levels and
assessment of adaptive behaviour skills by parents/caregivers
(Weisfeld-Adams et al 2013), suggesting a potential contribu-
tion of reduced methionine availability in the pathogenesis of
some of the clinical signs of the disease (Martinelli et al 2011a,
b). Nevertheless, severity scores showed no significant corre-
lation with methionine.
The only correlation observed with factors affected by
treatment, was the aforementioned relationship of total homo-
cysteine measured during the course of the disease and overall
impression.
Regarding possible genotype-phenotype correlations, re-
sults of mutation analysis showed that the homozygosity for
the c.271dupA mutation correlates with infantile presentation.
These findings support the previously suggested idea that
c.271dupA is associated with infantile onset. Homozygosity
for the c.394C>Tmutation was seen in six infantile presenting
patients and in four late presenting patients This apparent
contradiction with the previously reported correlation between
late onset and this mutation (Morel et al 2006; Nogueira et al
2008) may be related to differences in the classification of
patients.
Recently, the cblC defect has been included in some coun-
tries in the panel of diseases screened for by expanded new-
born screening (Carrillo-Carrasco et al 2012). However, nei-
ther the management nor the outcome of asymptomatic pa-
tients with cblC detected by newborn screening has been
extensively studied. At present there is only anecdotal data
suggesting that earlier diagnosis of affected subjects through
expanded newborn screening improves overall outcome but
not neurological and ocular symptoms (Weisfeld-Adams et al
2013; C. Dionisi-Vici personal observation). The report of a
family showing a non-neurological phenotype with fatal iso-
lated pulmonary hypertension at the age of 2 years in one
sibling and with haemolytic uremic syndrome at the age of
3 years in the eldest one (Iodice et al 2013), highlights the
possibility that if expanded newborn screening would have
been performed, these two brothers might have experienced a
different clinical outcome. Early intervention preceding the
appearance of severe signs related to micro-angiopathy might
well be expected to also avoid the occurrence of hydroceph-
alus, one of the more severe abnormalities occurring in the
cblC defect.
Taken together, these findings confirm that an exact com-
prehensive understanding of the pathophysiology of cblC
defect has still not been achieved. Lack of good developmen-
tal and neurological outcome may reflect possible irreversibil-
ity of pathogenetic mechanisms in this multifactorial defect.
Additionally, it is likely that the synergistic effect of different
838 J Inherit Metab Dis (2014) 37:831–840
mechanisms, which include the accumulation of putatively
toxic metabolites and the deficiency of products downstream
of the enzymatic defect(s), is responsible for the multisystem
organ involvement (Martinelli et al 2011a, b).
In summary, this survey points to the need for careful
prospective multi-centre studies as recently started with the
European Network and Registry for Homocystinurias and
Methylation Defects (E-HOD) using agreed treatment modal-
ities and monitoring parameters since present treatment re-
gimes do not fully improve the disease course.
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